Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, if we understand you correctly, you are saying the the FDA has been scammed by approving Generx to move to a fast-track Phase 3 clinical study after highly-successful Phase 1 and Phase 2 clinical trials?
Why don't you contact the FDA and explain all of this to them? They could probably use a good laugh.
ROTFLMAO. Failed Investment?
We've made most of our money in micro-caps by looking for catalysts that change the investment dynamics of a company.
CRXM has that, and more, in spades.
"In May 2020, after the period covered by this report, we entered into a Preferred Stock Purchase Agreement with Nostrum Pharmaceuticals, LLC (“Nostrum”), selling Nostrum 1,700,000 shares of our newly authorized Series B Convertible Preferred Stock in exchange for $1,700,000. Each share of Series B Convertible Preferred Stock is convertible into shares of Common Stock at a conversion ratio of 0.0113. Consequently the 1,700,000 shares are convertible into an aggregate of 150,442,478 shares of Common Stock. In addition, Nostrum entered into an agreement with Sabby Healthcare Master Fund Ltd. (“Sabby”), the sole holder of our outstanding Series A Convertible Preferred Stock, under which Nostrum purchased 220 shares of our Series A Convertible Preferred Stock from Sabby, which is convertible into 88,496 shares of common stock. Consequently, the 220 shares are convertible into an aggregate of 19,469,026 shares of Common Stock. Nostrum also agreed to purchase up to 570 additional Series A Convertible Preferred Stock from Sabby, within one year following the effective date of the transaction. Since May 2020, 397 shares of Series A Preferred Stock have been converted into 35,132,755 shares of our Common Stock (conversion rate of 88,496), that has increased our outstanding Common Stock to 49,622,154 shares as of March 31, 2021. As a result of these transactions, Nostrum currently controls approximately 75.2% of the voting interests of our Company."
The Series B Convertible Preferred Stock financing resulted in a reset of the conversion price of our outstanding Series A Convertible Preferred Stock, such that each Series A Convertible Preferred Stock is convertible into Common Stock at a conversion rate of 88,496. In a separate but concurrent transaction, when Nostrum acquired the 1,700,000 shares of Series B Convertible Preferred Stock, it also acquired 220 shares of Series A Convertible Preferred Stock from the current holder Sabby Healthcare Master Fund, Ltd., which is convertible into 19,469,026 shares of Common Stock. Nostrum also agreed to purchase the remaining up to 570 shares of Series A Convertible Preferred Stock from Sabby Healthcare Master Fund Ltd. within one year of the initial acquisition. Sabby Healthcare Master Fund, Ltd. retains the right prior to any such sale, to convert the Series A Convertible Preferred Stock prior to the anniversary. Since May 2020 and through March 31, 2021 a total of 397 shares of Series A Convertible Preferred Stock have been converted into 35,132,755 shares of Common Stock. As of March 31, 2021, there are 393 shares of Series A Convertible Preferred Stock outstanding including 220 held by Nostrum (convertible into 19,469,026 shares of Common Stock) and 173 shares held by Sabby Healthcare Master Fund Ltd. (convertible into 15,309,735 shares of Common Stock).
Each person has to make their own decisions based on what they determine is appropriate for them.
While we respect your choices, we intend to stay the course for the long-term rewards that we envision.
From the Super 10-K
As of December 21, 2020, there were approximately 100 stockholders of record of our common stock. Based on information we receive from brokerage firms in connection with proxy solicitations, we believe that there are approximately 5,000 beneficial owners of our common stock.
https://www.otcmarkets.com/filing/html?id=14889579&guid=eUnkkWVWxseYT3h
Did a bit of number crunching pertaining to the daily number of shares that have traded since the beginning of the year.
Up until yesterday 106,502,845 shares have changed hands, or roughly 2X the number of current shares outstanding.
We're only here to provide the data.
You will have to draw your own conclusions.
Date Open High Low Close Adj Close Volume
1/4/2021 0.04 0.05 0.04 0.04 0.04 1,868,300.00
1/5/2021 0.04 0.04 0.04 0.04 0.04 461,500.00
1/6/2021 0.04 0.04 0.03 0.04 0.04 1,734,900.00
1/7/2021 0.04 0.04 0.04 0.04 0.04 293,300.00
1/8/2021 0.04 0.04 0.04 0.04 0.04 433,100.00
1/11/2021 0.04 0.04 0.04 0.04 0.04 115,000.00
1/12/2021 0.04 0.04 0.03 0.04 0.04 322,200.00
1/13/2021 0.03 0.04 0.03 0.03 0.03 205,900.00
1/14/2021 0.04 0.04 0.03 0.04 0.04 199,800.00
1/15/2021 0.04 0.04 0.03 0.04 0.04 199,500.00
1/19/2021 0.04 0.04 0.04 0.04 0.04 130,400.00
1/20/2021 0.04 0.04 0.04 0.04 0.04 306,600.00
1/21/2021 0.04 0.04 0.04 0.04 0.04 195,500.00
1/22/2021 0.04 0.04 0.03 0.04 0.04 237,100.00
1/25/2021 0.04 0.04 0.03 0.03 0.03 254,100.00
1/26/2021 0.03 0.04 0.03 0.04 0.04 404,200.00
1/27/2021 0.04 0.04 0.04 0.04 0.04 50,500.00
1/28/2021 0.04 0.04 0.03 0.04 0.04 669,500.00
1/29/2021 0.04 0.04 0.04 0.04 0.04 372,400.00
2/1/2021 0.04 0.04 0.04 0.04 0.04 334,300.00
2/2/2021 0.04 0.04 0.04 0.04 0.04 130,500.00
2/3/2021 0.04 0.04 0.04 0.04 0.04 262,700.00
2/4/2021 0.04 0.05 0.04 0.05 0.05 181,700.00
2/5/2021 0.04 0.05 0.04 0.05 0.05 117,400.00
2/8/2021 0.05 0.05 0.04 0.04 0.04 281,600.00
2/9/2021 0.04 0.05 0.04 0.04 0.04 152,200.00
2/10/2021 0.04 0.06 0.04 0.05 0.05 1,238,800.00
2/11/2021 0.06 0.06 0.05 0.05 0.05 237,100.00
2/12/2021 0.05 0.05 0.05 0.05 0.05 407,100.00
2/16/2021 0.05 0.05 0.04 0.04 0.04 550,700.00
2/17/2021 0.04 0.04 0.04 0.04 0.04 439,700.00
2/18/2021 0.04 0.04 0.03 0.04 0.04 327,000.00
2/19/2021 0.04 0.04 0.04 0.04 0.04 496,000.00
2/22/2021 0.04 0.04 0.03 0.04 0.04 476,400.00
2/23/2021 0.04 0.04 0.04 0.04 0.04 994,100.00
2/24/2021 0.04 0.04 0.04 0.04 0.04 571,300.00
2/25/2021 0.04 0.05 0.04 0.05 0.05 2,015,400.00
2/26/2021 0.05 0.05 0.03 0.05 0.05 2,600,300.00
3/1/2021 0.05 0.05 0.04 0.04 0.04 662,500.00
3/2/2021 0.04 0.04 0.04 0.04 0.04 266,000.00
3/3/2021 0.04 0.04 0.04 0.04 0.04 26,000.00
3/4/2021 0.04 0.04 0.04 0.04 0.04 775,000.00
3/5/2021 0.04 0.04 0.03 0.04 0.04 229,200.00
3/8/2021 0.04 0.04 0.03 0.04 0.04 297,200.00
3/9/2021 0.04 0.04 0.04 0.04 0.04 60,300.00
3/10/2021 0.04 0.04 0.04 0.04 0.04 95,700.00
3/11/2021 0.05 0.05 0.04 0.04 0.04 963,300.00
3/12/2021 0.04 0.04 0.04 0.04 0.04 10,900.00
3/15/2021 0.04 0.04 0.04 0.04 0.04 23,900.00
3/16/2021 0.04 0.04 0.04 0.04 0.04 370,200.00
3/17/2021 0.04 0.04 0.04 0.04 0.04 296,600.00
3/18/2021 0.04 0.05 0.04 0.04 0.04 463,700.00
3/19/2021 0.04 0.05 0.04 0.04 0.04 975,500.00
3/22/2021 0.04 0.05 0.04 0.04 0.04 1,314,900.00
3/23/2021 0.04 0.04 0.04 0.04 0.04 162,300.00
3/24/2021 0.04 0.05 0.04 0.05 0.05 693,200.00
3/25/2021 0.05 0.05 0.05 0.05 0.05 1,088,700.00
3/26/2021 0.05 0.06 0.05 0.05 0.05 1,190,600.00
3/29/2021 0.05 0.06 0.05 0.05 0.05 1,094,600.00
3/30/2021 0.06 0.06 0.04 0.05 0.05 410,200.00
3/31/2021 0.05 0.05 0.05 0.05 0.05 494,100.00
4/1/2021 0.05 0.05 0.05 0.05 0.05 1,098,300.00
4/5/2021 0.05 0.05 0.04 0.05 0.05 731,700.00
4/6/2021 0.05 0.05 0.04 0.05 0.05 178,300.00
4/7/2021 0.05 0.05 0.05 0.05 0.05 227,100.00
4/8/2021 0.05 0.05 0.05 0.05 0.05 207,700.00
4/9/2021 0.05 0.05 0.05 0.05 0.05 440,200.00
4/12/2021 0.04 0.05 0.04 0.05 0.05 549,500.00
4/13/2021 0.05 0.05 0.05 0.05 0.05 347,500.00
4/14/2021 0.05 0.05 0.04 0.04 0.04 457,500.00
4/15/2021 0.04 0.05 0.04 0.04 0.04 1,258,700.00
4/16/2021 0.04 0.05 0.04 0.04 0.04 673,800.00
4/19/2021 0.04 0.04 0.04 0.04 0.04 288,900.00
4/20/2021 0.04 0.04 0.04 0.04 0.04 897,700.00
4/21/2021 0.04 0.04 0.04 0.04 0.04 160,800.00
4/22/2021 0.04 0.04 0.04 0.04 0.04 155,300.00
4/23/2021 0.04 0.06 0.04 0.05 0.05 11,604,100.00
4/26/2021 0.07 0.08 0.06 0.06 0.06 8,195,200.00
4/27/2021 0.06 0.06 0.05 0.06 0.06 2,542,200.00
4/28/2021 0.06 0.06 0.05 0.06 0.06 1,454,400.00
4/29/2021 0.06 0.06 0.05 0.06 0.06 1,015,600.00
4/30/2021 0.06 0.06 0.05 0.06 0.06 1,562,900.00
5/3/2021 0.06 0.06 0.05 0.06 0.06 358,100.00
5/4/2021 0.05 0.06 0.05 0.06 0.06 1,057,200.00
5/5/2021 0.06 0.06 0.05 0.06 0.06 957,400.00
5/6/2021 0.05 0.06 0.05 0.05 0.05 245,800.00
5/7/2021 0.05 0.06 0.05 0.05 0.05 810,900.00
5/10/2021 0.05 0.06 0.05 0.05 0.05 722,400.00
5/11/2021 0.05 0.06 0.05 0.05 0.05 389,300.00
5/12/2021 0.06 0.06 0.05 0.05 0.05 305,900.00
5/13/2021 0.05 0.05 0.05 0.05 0.05 1,221,000.00
5/14/2021 0.05 0.05 0.04 0.05 0.05 1,120,600.00
5/17/2021 0.05 0.05 0.04 0.04 0.04 3,086,000.00
5/18/2021 0.04 0.04 0.04 0.04 0.04 909,600.00
5/19/2021 0.04 0.04 0.04 0.04 0.04 1,040,500.00
5/20/2021 0.04 0.05 0.04 0.05 0.05 721,600.00
5/21/2021 0.04 0.05 0.04 0.05 0.05 811,100.00
5/24/2021 0.05 0.05 0.05 0.05 0.05 356,500.00
5/25/2021 0.05 0.05 0.04 0.05 0.05 249,300.00
5/26/2021 0.05 0.05 0.04 0.05 0.05 699,100.00
5/27/2021 0.05 0.05 0.04 0.05 0.05 465,000.00
5/28/2021 0.05 0.05 0.04 0.05 0.05 727,600.00
6/1/2021 0.05 0.05 0.04 0.05 0.05 907,200.00
6/2/2021 0.05 0.05 0.05 0.05 0.05 364,200.00
6/3/2021 0.05 0.05 0.05 0.05 0.05 317,000.00
6/4/2021 0.05 0.05 0.04 0.04 0.04 220,900.00
6/7/2021 0.05 0.05 0.04 0.05 0.05 414,400.00
6/8/2021 0.05 0.05 0.04 0.05 0.05 217,700.00
6/9/2021 0.04 0.05 0.04 0.04 0.04 513,600.00
6/10/2021 0.04 0.05 0.04 0.05 0.05 635,600.00
6/11/2021 0.05 0.05 0.04 0.05 0.05 495,300.00
6/14/2021 0.05 0.05 0.04 0.05 0.05 235,200.00
6/15/2021 0.04 0.05 0.04 0.05 0.05 414,800.00
6/16/2021 0.05 0.05 0.04 0.05 0.05 402,200.00
6/17/2021 0.05 0.06 0.05 0.05 0.05 714,500.00
6/18/2021 0.06 0.06 0.05 0.05 0.05 533,600.00
6/21/2021 0.05 0.05 0.05 0.05 0.05 533,100.00
6/22/2021 0.05 0.05 0.05 0.05 0.05 289,600.00
6/23/2021 0.05 0.05 0.05 0.05 0.05 303,600.00
6/24/2021 0.05 0.06 0.04 0.05 0.05 2,338,800.00
6/25/2021 0.06 0.06 0.04 0.05 0.05 645,700.00
6/28/2021 0.04 0.05 0.04 0.05 0.05 437,900.00
6/29/2021 0.05 0.05 0.04 0.05 0.05 693,700.00
6/30/2021 0.05 0.05 0.04 0.05 0.05 285,000.00
7/1/2021 0.05 0.05 0.04 0.05 0.05 495,300.00
7/2/2021 0.04 0.05 0.04 0.05 0.05 1,104,900.00
7/6/2021 0.05 0.05 0.05 0.05 0.05 428,000.00
7/7/2021 0.05 0.06 0.05 0.06 0.06 595,200.00
7/8/2021 0.06 0.06 0.05 0.06 0.06 381,300.00
7/9/2021 0.06 0.06 0.05 0.06 0.06 925,600.00
7/12/2021 0.06 0.06 0.05 0.05 0.05 570,000.00
7/13/2021 0.06 0.06 0.05 0.05 0.05 519,500.00
7/14/2021 0.05 0.06 0.05 0.05 0.05 703,800.00
7/15/2021 0.05 0.05 0.04 0.05 0.05 1,594,900.00
7/16/2021 0.05 0.05 0.04 0.05 0.05 932,700.00
7/19/2021 0.04 0.05 0.04 0.05 0.05 221,600.00
7/20/2021 0.05 0.05 0.04 0.05 0.05 659,100.00
7/21/2021 0.05 0.05 0.05 0.05 0.05 295,500.00
7/22/2021 0.05 0.05 0.05 0.05 0.05 578,700.00
7/23/2021 0.05 0.05 0.05 0.05 0.05 610,800.00
7/26/2021 0.05 0.05 0.05 0.05 0.05 480,100.00
7/27/2021 0.05 0.06 0.05 0.05 0.05 496,500.00
7/28/2021 0.05 0.06 0.05 0.05 0.05 155,700.00
7/29/2021 0.05 0.05 0.05 0.05 0.05 254,400.00
7/30/2021 0.0545 0.0545 0.051 0.05345 0.05345 50,645.00
106,502,845.00
If you are a true long-term investor, it doesn't matter.
Those who have doubts can always sell no matter what, but the trading restrictions will take away the ability for investors to purchase new shares.
The way we look at it.....you've got roughly two weeks, if you are a Schwab of TD Ameritrade client, to load the boat.
Could this be the time to get locked and loaded?
Even if they get slapped with a trading restriction on their shares, they can always get reinstated after they file and become current.
Some folks always seem to be picking the fly shit out of the pepper.
Does anyone really believe that with the amount of time invested by Chris Reinhard, and the amount of money invested by Nostrum, that these guys are going to let a potential opportunity to bring a billion dollar drug to market fall by the wayside?
We've been investing in micro-caps companies for years, and not a single one of them has not had their fair share of difficult challenges along the way. One even went through Chapter 11 Bankruptcy only to emerge in a much stronger position.
The time to buy these little gems is when the level of hope and confidence among retails investors is at its absolute lowest level. Our experience is that it truly is darkest before the dawn, when it comes to micro-cap investing.
We believe, as we did with CELH and GLUC, that CRXM will have its day to shine. Those who are carrying umbrellas, and are expected rain to pour down, will regret their short-sighted view of the future for this company.
We've got on our shades and sunscreen.
https://xconomy.com/san-diego/2017/04/04/angionetics-nears-key-gene-therapy-trial-for-coronary-heart-disease/
Just a point of clarification for all.
Even if a pink sheet company fails to meet the requirements by the deadline date, that company can still become current and have their status reinstated or changed to reflect the fact that they have become pink sheet current.
At that point, their shares would then be eligible to have any and all trading restrictions lifted.
This IS NOT a one time, static policy and once a company is placed on the restricted list, it in no way means that they will stay there forever.
Companies that meet the requirements now, could fall back and be placed on the restricted list in the future, just as companies that would not meet the requirements now can meet them in the future and be reconsidered to be placed back on full trading status.
It seems like he never took Mr. Fleming up on his offer. Too bad.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163088198
Sabby sold their entire interest to Nostrum awhile back. Go back and read the filings, along with the Preferred Stock Purchase Agreement signed in May of 2020.
https://contracts.justia.com/companies/gene-biotherapeutics-inc-7110/contract/119376/
It doesn't matter whether Nostrum is a public or private company. That is irrelevant. They are deemed to have a "controlling interest" in CRXM. As such they are considered an "affiliate" and must file SEC documents regarding any change in their ownership position within 2 business days.
https://www.investopedia.com/terms/a/affiliatedperson.asp
The Series B Convertible Preferred Stock financing resulted in a reset of the conversion price of our outstanding Series A Convertible Preferred Stock, such that each Series A Convertible Preferred Stock is convertible into Common Stock at a conversion rate of 88,496. In a separate but concurrent transaction, when Nostrum acquired the 1,700,000 shares of Series B Convertible Preferred Stock, it also acquired 220 shares of Series A Convertible Preferred Stock from the current holder Sabby Healthcare Master Fund, Ltd., which is convertible into 19,469,026 shares of Common Stock. Nostrum also agreed to purchase the remaining up to 570 shares of Series A Convertible Preferred Stock from Sabby Healthcare Master Fund Ltd. within one year of the initial acquisition. Sabby Healthcare Master Fund, Ltd. retains the right prior to any such sale, to convert the Series A Convertible Preferred Stock prior to the anniversary. Since May 2020 and through March 31, 2021 a total of 397 shares of Series A Convertible Preferred Stock have been converted into 35,132,755 shares of Common Stock. As of March 31, 2021, there are 393 shares of Series A Convertible Preferred Stock outstanding including 220 held by Nostrum (convertible into 19,469,026 shares of Common Stock) and 173 shares held by Sabby Healthcare Master Fund Ltd. (convertible into 15,309,735 shares of Common Stock).
https://www.otcmarkets.com/filing/html?id=14889579&guid=uO8kk6g3WIQmT3h
There will most likely be a relief rally and a short-term pop in the share price. The really big move comes if they finally get FDA approval to bring Generx to the market.
This drug could be worth billions.
We actually look at this as a long-term (LEAPS) option play. It's going to be a binary outcome; one way or another.
The stock will fly if everything falls into place. If not, it will expire, and become worthless, just like an option.
It's going to take brass ones to hold these shares for the huge payoff.
Only long-term investors, who buy and hold, will make the big money.
The traders will merely get the crumbs that fall from the table.
We get it.
We were speaking from the perspective of the average retail investor.
It is easy to understand the concern that some investors have regarding the new trading restrictions that go into effect in late September.
Any OTC company that is non-reporting, and fails to make material information available through public disclosures, will have trading in their shares limited to only long shareholders being able to liquidate their positions. In other words, no new buying will be allowed.
If broker/dealers will only allow existing shareholders to sell their current positions, and if nobody is allowed to buy shares, who will the sellers be able to sell to?
CRXM management should understand this concern among their shareholders, and get current as soon as possible. Investors are not going to wait until the 11th hour before taking whatever action they deem necessary to protect themselves from any adverse fallout which may occur once the new rules go into effect.
Some on this thread will continue to pontificate that it is coming..... but so is Christmas.
Talk is cheap, and actions always speak louder than words.
The silence from CRXM management is deafening.
Actually, "technically speaking" GLUC is a penny stock.
"In the past, penny stocks were considered any stocks that traded for less than one dollar per share. The U.S. Securities and Exchange Commission (SEC) has modified the definition to include all shares trading below five dollars."
https://www.investopedia.com/terms/p/pennystock.asp
As for your theory that it has been all of those "cheap shares", issued in past financing deals, that are the ones being sold over the past three years, we would remind you that all of those shares are "restricted" for a period of two years, under SEC Rule 144.
Restricted securities are securities acquired in unregistered, private sales from the issuing company or from an affiliate of the issuer. Investors typically receive restricted securities through private placement offerings, Regulation D offerings, employee stock benefit plans, as compensation for professional services, or in exchange for providing "seed money" or start-up capital to the company. Rule 144(a)(3) identifies what sales produce restricted securities.
https://www.sec.gov/reportspubs/investor-publications/investorpubsrule144htm.html
It’s extremely difficult for us to believe all of the supposed buying you claim to be doing every day without seeing an SEC filing disclosing such a large position.
Surely, your position exceeds 5% of the almost 50 million shares outstanding. Doesn’t it?
You've been saying that for months now, and there has been nothing but crickets.
Continuing to post on the "expectation" of news serves absolutely no purpose.
Why not just wait like the rest of us and comment on the news once it gets released by the company?
Extremely unlikely.
CRXM is a long-term story. Scams don't generally last that long.
Chris Rheinhard has been working on this drug therapy for over 25 years.
https://xconomy.com/san-diego/2017/04/04/angionetics-nears-key-gene-therapy-trial-for-coronary-heart-disease/
Claims of CRXM being a scam are totally baseless.
We doubt that Nostrum is behind the recent selling.
First of all, they have no common stock, only preferred shares which are convertible into common shares.
Assuming that they did convert some of those preferred shares into common, and then sold the common shares, they would be required to file with the SEC disclosing their activities within 2 business days.
We have not seen any such filing by Nostrum, hence our conclusion that they have not sold any CRXM shares in the open market.
That would be very short-sighted of them to do something like that.
It's akin to stepping over dollars to pick up dimes.
<<"If" Nostrum were to sell all of their shares at .046 they would realize a gain of 400%.>>
We seriously doubt that Nostrum would have invested $1.7 million in an supposed "scam".
More likely, they did some serious vetting of the company, the Generx drug therapy, and the CEO.
Do you think that the FDA would have granted fast-track Phase III status to a scam company?
ROTFLMAO.
We agree that there a a lot of bad actors on the OTC Pinks, but we don't believe that Chris Reinhard is one of them.
It sounds like perhaps you should have done this as part of your due diligence before you made an investment in CRXM.
For our part, we have done extensive due diligence on this company and do not see the importance of this in the overall context of things.
But then again, to each his own. GLTY.
We too, appreciate a thoughtful discussion from both sides on relevant issues.
Unfortunately, that whole nonsense about an incorrect address was ridiculous. It was nothing but a wild goose chase and a fishing expedition.
The company address is listed on their website and in their SEC filings.
There is no need to look any further into something that has so little to do with an intelligent discourse regarding the company and their Generx drug therapy.
So, are we to assume that you are accusing them of filing false information in an SEC document?
Why don't you just look at the most recent SEC Filing dated 4/23/2021?
11230 Sorrento Valley Rd., Suite 220
San Diego, California 92121
(858) 414-1477
(Address of principal executive offices)
https://www.otcmarkets.com/filing/html?id=14889579&guid=Cs9kkFmjSlWJDyh
Another useless piece of information.
What is your point?